Sodium-Glucose Co-transporter-2 Inhibitor of Dapagliflozin Attenuates Myocardial Ischemia/Reperfusion Injury by Limiting NLRP3 Inflammasome Activation and Modulating Autophagy

Background: The sodium-glucose co-transporter-2 (SGLT-2) inhibitor dapagliflozin improves cardiovascular outcomes in patients with type 2 diabetes in a manner that is partially independent of its hypoglycemic effect. These observations suggest that it may exert a cardioprotective effect by another m...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Yong-Wei, Que, Jia-Qun, Liu, Shuai, Huang, Kai-Yu, Qian, Lu, Weng, Ying-Bei, Rong, Fang-Ning, Wang, Lei, Zhou, Ying-Ying, Xue, Yang-Jing, Ji, Kang-Ting
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Cardiovascular Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8785320/
https://www.ncbi.nlm.nih.gov/pubmed/35083298
http://dx.doi.org/10.3389/fcvm.2021.768214

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8785320/
https://www.ncbi.nlm.nih.gov/pubmed/35083298
http://dx.doi.org/10.3389/fcvm.2021.768214

Ejemplares similares